electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Shanghai Tianci Life Science Development Co., Ltd., established on 2018-06-14, The scope of business includes engaging in biotechnology,Medical Technology,Ecotechnology,Technology development in the field of information technology,technical consulting,technology transfer,Technical Services,Research and development of biological reagents for non-clinical diagnosis,business inquiries. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

NeuroGenesis, Inc. manufactures and markets nutritional supplements of a particular type. Its products are designed to increase the health of people suffering from a variety of mental and physical health disorders, such as hyperactivity, effects of anxiety and reactions to stressful situations, addictions and other physical disorders. The company was founded on November 13, 1984 and is headquartered in League City, TX.

Chemyunion is a privately owned chemical company. It manufactures cosmetic ingredients, pharmaceutical excipients, and food and veterinary inputs, as well as actives for hygiene and cleaning. It develops products that are recognized for their high levels of performance and value, in addition to remaining current with the latest trends and demands in beauty, health, and wellbeing.

Part of Lantheus Holdings, Inc., Progenics Pharmaceuticals Nevada, Inc. is a company headquartered in the United States that manufactures pharmaceutical products.

Suzhou Xingzhou Biotechnology Co., Ltd., established on 2020-08-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Biochemical product technology research and development;Engineering and Technology Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

Part of Ease Asset Management Ltd., TTI Ellebeau, Inc. is a Japanese company located in Tokyo that develops, manufactures, and distributes medicinal and quasi drugs. The firm was acquired by Ease Asset Management Ltd. from Pine Capital Group Ltd. on April 21, 2014.